Non Hodgkin Lymphoma Clinical Trial
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
Summary
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus, sirolimus, antithymocyte globulin, and methotrexate before and after transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well sirolimus, tacrolimus, and antithymocyte globulin work in preventing graft-versus-host disease in patients undergoing a donor stem cell transplant for hematological cancer .
Full Description
OBJECTIVES:
Primary
To determine the incidence and severity of acute- and chronic-graft-versus-host disease (GVHD) after HLA-matched or -mismatched unrelated donor hematopoietic peripheral blood transplantation in patients with hematologic malignancies scheduled to receive immunosuppressive combination of sirolimus, tacrolimus, and anti-thymocyte globulin as GVHD prophylaxis.
To determine the safety of this combination in the first six months post-transplant.
Secondary
To determine the time-to-engraftment, non-relapse mortality rate, overall and disease-free survival, incidence of disease relapse, and incidence of opportunistic infections with this GVHD prophylaxis.
OUTLINE: Patients are stratified according to conditioning regimen (fludarabine phosphate and melphalan vs fractionated total-body irradiation [FTBI] and etoposide vs FTBI and cyclophosphamide) and degree of donor/recipient HLA mismatch (high-risk vs low-risk).
Conditioning regimen: Patients receive 1 of 3 standard conditioning regimens beginning on day -9 or -8 and continuing to day -1 or 0.
Peripheral blood stem cell transplantation: Patients receive HLA-matched or mismatched unrelated donor peripheral blood stem cells on day 0.
Graft-versus-host disease prophylaxis: Patients receive tacrolimus IV continuously beginning on day -3 and then orally when tolerated, oral sirolimus on days -3 and -2, anti-thymocyte globulin IV over 4-8 hours on days -3 to 0, and methotrexate* IV on days 1, 3, and 6. Tacrolimus and sirolimus continue for 3-6 months (with taper).
NOTE: *Only patients with high-risk HLA mismatch receive treatment with methotrexate.
After completion of study therapy, patients are followed periodically for up to 2 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Diagnosis of hematological malignancy including any of the following:
Non-Hodgkin lymphoma (NHL) in any complete remission (CR) or partial response (PR)
Hodgkin lymphoma in any CR or PR
Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in any CR
Bone marrow blasts < 20% within 4 weeks of transplant and peripheral blood absolute blast count < 500/µL on the day of initiation of conditioning for patients with non-CR AML or ALL
Myelodysplastic syndromes (MDS) treated or untreated
Chronic myelogenous leukemia (CML) in chronic or accelerated phase
Multiple myeloma in any CR or PR
Chronic lymphocytic leukemia in CR or PR 2 or greater
Myelofibrosis and other myeloproliferative disorders
Bone marrow blasts < 20% within 4 weeks of transplant and peripheral blood absolute blast count < 500/µL on the day of initiation
High-risk disease defined as AML or ALL > CR1, accelerated phase CML, recurrent aggressive lymphoma, or active lymphoproliferative disease at transplant
Low-risk disease defined as AML or ALL in CR1, chronic phase CML, or low-grade lymphoproliferative disorder with controlled disease at transplant
Must be planning to receive 1 of the following conditioning regimens at City of Hope:
Fludarabine phosphate and melphalan for patients with hematological malignancies and contraindications for conventional myeloablative regimens due to age, co-morbidity, or previous transplant
Fractionated total-body irradiation (FTBI) and etoposide for patients with AML and ALL or CML in accelerated phase
FTBI and cyclophosphamide for patients with NHL, AML, CML, and MDS
Suitable unrelated donor available
HLA-matched or mismatched
Peripheral blood stem cells available
No bone marrow or ex vivo-engineered or processed graft (e.g., CD34-positive, T-cell depletion)
No uncontrolled CNS disease
PATIENT CHARACTERISTICS:
Karnofsky performance status (PS) 70-100% or ECOG PS 0-2
Creatinine < 1.3 mg/dL or creatinine clearance ≥ 70 mL/min
Ejection fraction > 45%
Direct bilirubin < 3 times upper limit of normal (ULN)
ALT and AST < 3 times ULN
Forced vital capacity, FEV1, and DLCO > 45% of predicted
Able to cooperate with oral medication intake
No active donor or recipient serology positive for HIV
No known contraindication to administration of sirolimus, tacrolimus, or anti-thymocyte globulin
No active hepatitis B or C
Negative pregnancy test
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
Concurrent participation in other clinical trials for prevention or treatment of viral, bacterial, or fungal disease allowed provided agents do not interact with agents used in the current study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Phoenix Arizona, 85006, United States
Duarte California, 91010, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.